Results 21 to 30 of about 52,225 (202)
Di-san junyi daxue xuebao, 2021 Objective To investigate the laboratory and clinical characteristics of acute lymphoblastic leukemia (ALL) with e1a3 BCR-ABL fusion protein. Methods The clinical data, and results of bone marrow cytology, flow cytometry, karyotyping, fluorescence in situ
CHEN Siyu +6 more
doaj +1 more source
Imatinib restores expression of CD62L in BCR-ABL-positive cells [PDF]
Journal of Leukocyte Biology, 2003 Abstract Chronic myelogenous leukemia (CML) is characterized by aberrant trafficking of malignant hematopoietic progenitor cells in the peripheral blood. Expression of the cell adhesion molecule CD62L was reported to be significantly lower in CML patients than in normal controls. We studied whether the transcription of CD62L in CML cells
S, Fruehauf +7 more
openaire +2 more sources
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
Haematologica, 2010 Background Selective inhibition of the BCR-ABL tyrosine kinase by RNA interference has been demonstrated in leukemic cells. We, therefore, evaluated specific BCR-ABL small interfering RNA silencing in BCR-ABL-positive cell lines, including those ...
Michael Koldehoff +3 more
doaj +1 more source
Molecular Cancer, 2022 Background Dysregulation of long noncoding RNAs (lncRNAs) has been linked to various human cancers. Bcr-Abl oncogene that results from a reciprocal translocation between human chromosome 9 and 22, is associated with several hematological malignancies ...
Yun Ma +7 more
doaj +1 more source
Cell Reports, 2013 Chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias are characterized by the t(9;22) chromosome, which encodes the BCR/ABL oncogene. Multiple mouse models of CML express BCR/ABL at high levels from non-Bcr promoters, resulting in the ...
Samantha B. Foley +6 more
doaj +1 more source
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells
BMC Cancer, 2011 Background The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of ...
Chai Juin Hsien +5 more
doaj +1 more source
Hematology/Oncology and Stem Cell Therapy, 2008 BACKGROUND: Expression of myeloid or T cell lymphoid in precursor B cell acute lymphoblastic leukemia (pre- B cell ALL), which is referred to as aberrant expression, is quite a common phenomenon. cD66c is a myeloid marker which has aberrant expression in
Tarek M. Owaidah +3 more
doaj +1 more source
DETECTION OF BCR-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA PATIENTS USING IMMUNOCYTOCHEMISTRY
The Iraqi Journal of Medical Sciences, 2016 Background: Chronic Myeloid leukemia (CML) is a myeloproliferetive disorder associated with chromosomal abnormality, Philadelphia chromosome (Ph), in more than 95% of CML patients. The resulting BCR-ABL fused gene is markers for this type of leukemia. In
Maysaa Abdul Razaq Dhahi +2 more
doaj +6 more sources
An In-house Method for Molecular Monitoring of BCR-ABL
Turkish Journal of Hematology, 2012 OBJECTIVE: At present in Turkey, centers that are able to give reliable RQ-PCR BCR-ABL results are limited in number. We aimed to describe a cost-effective, in-house method for BCR-ABL quantification and to illustrate an example for RQ-PCR validation ...
Hakkı Ogun Sercan +4 more
doaj +1 more source
Molecular Cancer, 2012 Background Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I ...
Fei Fei +5 more
doaj +1 more source